Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaZa: zanubrutinib in primary cold agglutinin disease
2023-505746-25-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in cold agglutinin disease (CAD), sponsored by HOVON. Primary endpoint: CAD response rate after 6 cycles. Planned start Apr 2024; status: authorised.
02
Drugs
zanubrutinib
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on 2023-505746-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505746-25-00.